🇺🇸 FDA
Pipeline program

Favipiravir

FAVI-PK-2017001

Phase 2 small_molecule completed

Quick answer

Favipiravir for Influenza, Human is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Influenza, Human
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials